Live at 10 AM Tomorrow | New Opportunities in the Changing Landscape of Drug R&D
See you tomorrow at 10 a.m. sharp.
The second installment of the "FreeS Fund Dialogue" livestream series on biotech and pharma — New Opportunities Amid a Changing Drug Discovery Landscape — goes live tomorrow morning (November 14) at 10 a.m. sharp. Ning Xia, founder and CEO of ChemAIRS, and Yikai Wang, founder and CEO of Koin Pharmaceuticals, will join Lei Wang, partner at FreeS Fund, for an in-depth conversation.
/ 01 / How to Watch
Tune in via Zoom, Baidu Finance, Sina Tech, Sina Finance, or the FreeS Fund WeChat Channels account. Details for each platform below — take your pick.
Zoom Livestream
We've already sent out the first wave of Zoom webinar invites by email. A limited number of spots remain open — scan the QR code to register and join the Zoom room for real-time interaction with our guests. Keep an eye on your inbox for the participation link.
Scan to register 👆
Baidu Finance Livestream
Tomorrow at 10:00 a.m., scan the QR code in the image below to watch the livestream in the Baidu app.
Scan to reserve your spot 👆
If the link won't open after scanning, hit your phone's back button — the livestream page should appear.
Sina Tech & Sina Finance Livestream
Tomorrow at 10:00 a.m., scan the QR code below to watch on Sina Tech and Sina Finance.
Scan to reserve your spot 👆
If the link won't open after scanning, hit your phone's back button — the livestream page should appear.
WeChat Channels Livestream
Tap the reservation button above to book your spot now — Channels will send you a reminder when we go live. Tomorrow at 10:00 a.m., just open Channels and you're in.
/ 02 / Topics
The conversation will cover, but won't be limited to:
- What new variables have reshaped drug discovery in recent years? How did the two founders spot their opportunities?
- Why start a company? What's the core moat?
- How can emerging biotech startups coexist and thrive alongside big pharma?
- What's the outlook for novel tool platforms and new-model biotech companies? From finding an entry point to becoming an industry player — how long is the road?
- How can talent from medicinal chemistry, organic chemistry, AI, and other backgrounds leverage their strengths in new drug R&D?
/ 03 / Special Thanks
Our sincere gratitude to the following organizations for their support:
Baidu Finance, Sina Tech, Sina Finance
Peking University Alumni Entrepreneur Federation, CEO (Chinese Entrepreneurs Organization), CMU SUMMIT (Carnegie Mellon University U.S.-China Innovation and Entrepreneurship Summit), Harvard Venture Club, Harvard CSSA, MITCEO, Puzhi Academy, Yale Entrepreneur Association (YEA), China World Youth Summit, China-UK Youth Elite Summit
Tomorrow at 10 a.m. (November 14). See you there.
▲ How We Think About the Present and Future of Drug Discovery | FreeS Fund Dialogue Vol. 2 — Final 2 Days to Register ▲ Why Is AI Drug Discovery So Hot, and Why Now? | FreeS Fund Biotech & Pharma VC Summit Recap ▲ FreeS Report 23: Crossing the "Valley of Death": Systemic New Opportunities in Small-Molecule New Drug R&D ▲ Early-Stage Medical Aesthetics Investment Turns to Underlying Technology | FreeS Research
Star the FreeS Fund WeChat official account for first-hand industry research.
